

Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment

Puzi Jiang

Huazhong University of Science and Technology

Senying Lai

Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University

Sicheng Wu

Huazhong University of Science and Technology School of Foreign Languages

Xing-Ming Zhao

Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University

Wei-Hua Chen (✉ weihuachen@hust.edu.cn)

<https://orcid.org/0000-0001-5160-4398>

Research article

Keywords: Colorectal cancer, Crohn's disease, gut microbiota, diagnostic biomarkers, treatment response, machine learning

Posted Date: March 13th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-17100/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Compromised intestinal barrier (CIB) has been associated with many enteropathies, including colorectal cancer (CRC) and inflammatory bowel disease (IBD). We hypothesized that CIB could lead to increased host-derived contents including epithelial cells into the gut, change its physio-metabolic properties, and globally alter microbial community and metabolic capacities.

Results

Consistently, we found host DNA contents (HDCs), calculated as the percentage of metagenomic sequencing reads mapped to the host genome, were significantly elevated in patients of CRC and Crohn's disease (CD). Consistent with our hypothesis, we found that HDC correlated with microbial- and metabolic-biomarkers of these diseases, contributed significantly to machine-learning models for patient stratification and was consequently ranked as a top contributor. CD patients with treatment could partially reverse the changes of many CD-signature species over time, with reduced HDC and fecal calprotectin (FCP) levels. Strikingly, HDC showed stronger correlations with the reversing changes of the CD-related species than FCP, and contributed great in classifying treatment responses, suggesting that it was also a biomarker for effective treatment.

Conclusions

Together, we identified a novel biomarker from fecal metagenomics for intestinal diseases and effective treatment; our results also suggested that host-derived contents may have greater impact on gut microbiota than previously anticipated.

Background

Colorectal cancer (CRC) is the 3rd most common cancer worldwide and the 2nd leading cause of cancer-related death in the United States [1, 2]; in recent years, the incidence of CRC has been increasing in young adults in major western countries [3, 4]. Similarly, Crohn's disease (CD) is also increasing worldwide and can be attributed largely to industrial urbanization and Western life-styles [5]. As genetics could only explain limited proportions of the CRC [6, 7] and CD [8] incidences, researchers have recently linked it to environmental factors, life styles and gut microbiota dysbiosis [8–13]. By contrasting gut microbiome profiles of CRC and CD patients to that of the healthy controls, researchers have identified bacterial species that were specifically enriched in CRC [10–12, 14] and CD [13] respectively; many of the CRC-enriched species were recently found to be consistent across populations, according to two meta-analysis studies [15, 16]. In addition, microbial genes involved in various biological pathways were also enriched in the gut microbiota of CRC [10, 15, 16] and CD [13] patients. Both the differential species and pathways can be used as non-invasive markers for patient stratification [10, 11, 13, 15, 16]. These findings greatly improved our understanding on the potential roles of gut microbiota in the pathogenesis and/or

development of these intestinal diseases, and implied a global alteration of the local gut environment in the patients.

The performance of gut microbiota profiling on disease diagnosis can be further improved in combination with clinical tests measuring human conditions including fecal occult blood test (FOBT) and fecal calprotectin (FCP) test [10, 17]. FOBT measures hidden blood in stool samples, indicating intestinal injury, while FCP produced by neutrophils due to activation or cell death serves as a biomarker of gut inflammation; they are markers for intestinal diseases but suffered from low specificity and sensitivity. Although clinically feasible and cost effective, it is not trivial to combine these measurements with fecal microbial profiling results. Moreover, Crohn's disease as a chronic and intractable gastrointestinal disease, need to be diagnosed and assessed therapy response via colonoscopy, questionnaires and stool calprotectin estimation, of which are either invasive test or inconstant due to physical status [18, 19].

Compromised intestinal barrier (CIB) has been shown to associate with many intestinal diseases, including inflammatory bowel diseases (IBD) [20] and CRC [21, 22]. CIB could be caused by infection, lesion, and/or inflammation, manifested as a thinner mucus layer and leaky barrier, and consequently led to increased host-derived contents from epithelial cells and blood shedding into lumen [23]. In other words, CIB could lead to increased host DNAs in feces of patients with intestinal diseases; the more severe the diseases, the higher host DNA contents. Previous researches have detected increased human DNAs in feces from patients with intestinal diseases [24–26]. Since fecal metagenomics are obtained using whole-genome shotgun sequencing and contain unbiased survey on bacterial, viral and host DNA contents (HDCs) [13, 26], we could directly calculate the HDC as the percentage of the gut metagenomics sequencing reads mapped to the human genome (see Methods) for each fecal sample and use it as a proxy of CIB as well as a convenient approximation for FOBT and FCP tests. Furthermore, the increased host-derived contents due to CIB could alters the physio-metabolic properties of the gut environment, stimulates pro-inflammatory pathways [27] and consequently leads to global alterations in gut microbiota composition as a result of complex interplay between microbiome and host. We thus would expect that HDC, as an indicator of CIB, may also correlate with the disease-associated species and altered metabolic pathways.

In this study, we collected nine metagenomic datasets from two most common intestinal diseases and performed the analysis to (1) confirm that HDCs elevated in the patients signify microbial dysbiosis; (2) test whether HDC can further improve performance of machine learning models in patient stratification in combination with metagenomic profiles, and (3) evaluate the contribution of HDCs and HDC related microbes to these models. We also analyzed the potential of HDC and microbiome for predicting treatment response to investigate the feasibility of solely fecal metagenomics data as non-invasive test.

Results

Increased human DNA contents (HDCs) in CRC patients

We first focused on CRC. As expected, we found that HDCs were significantly higher in feces of CRC patients than that of the healthy controls in all seven CRC datasets (Fig. 1a, Tables S1 and Tables S2). We then identified in total 26 species that were significantly correlated with HDCs in at least two datasets (Spearman Rank Correlation, p -value < 0.05 , Fig. 1b; see Methods and Table S3). Among which, thirteen overlapped with the CRC microbial signatures with markedly differential abundances identified in at least two datasets (adjusted p -value < 0.05 , see Methods), including twelve CRC-enriched species (Fig. 1b), such as *Fusobacterium nucleatum*, *Bacteroides fragilis* and *Peptostreptococcus stomatis*, which were found in two recent meta-analyses of CRC [15, 16]. Microbial colonization varies along the colon, partly because of thickness of mucous layer. Previous studies showed the *B.fragilis* with the capability of glycoproteins degradation and toxin production could penetrate the protective mucous layer, suggesting the bacteria accelerate the injury of gut barrier, trigger inflammation and induce tumorigenesis [28–30]. We also identified forty metabolic pathways that were significantly correlated with HDCs in at least two datasets (Table S4); among which, sixteen were previously identified as metabolic-pathway-biomarkers for CRC (see Methods). Most of the HDC-related functions decreased in at least three datasets were related to carbohydrate degradation for production of energy and short-chain fatty acids, such as D-galactose degradation and sucrose degradation (Fig. 1c) [31]. In addition, HDC negatively correlated with the degradation pathways of several monosaccharides and monosaccharide derivatives, including fucose, mannose, galactose and UDP-N-acetyl-D-glucosamine (Table S4), which are known building blocks of gut mucus glycans; these results indicated decreased concentrations of the monosaccharides and derivatives, further confirming that the intestinal barrier is compromised [30]. Together, our results suggested that ClB, as indicated by HDCs that can be directly quantified from gut metagenomics data, maintained a relationship with gut microbiota dysbiosis both in taxonomic and functional levels.

Combination of HDC and microbiome contributed significantly to patient stratification

We next tested if HDC and correlated species and pathways (referred as to HDC-species and HDC-pathways respectively) could contribute to patient stratification in CRC. Similar to Wirbel et al [15] and Thomas et al [16], we performed a leave-one-dataset-out (LODO) analysis [32] in which Random forest classifiers were trained on the combined datasets of all but one, and tested on the one that was left-out; we did this for each dataset in turn. As shown in Fig. 2a and 2c, for models trained using species and pathways abundances, including HDCs could improve prediction performance. More importantly, HDC was ranked as a top important feature, i.e. the 4th and 1st in the taxonomic (Fig. 2b) and functional (Fig. 2d) models, respectively. Interestingly, both HDC-related models performed better than models based on altered markers, even though overlap existed in the taxonomic and functional features (Fig. 2a, 2b). These results indicated the HDC-correlated features could contribute substantially to patient stratification and disease diagnosis (Fig. 2).

Similar results were found in CD

We then checked if similar results could be found in CD. A previous study reported elevated fecal HDCs in pediatric CD as compared with healthy controls [13]; the authors used quantitative polymerase chain reaction (QPCR) method to quantify HDCs by targeting human beta-tubulin coding-sequences. The authors also calculated HDCs from the metagenomics data and reported that the QPCR results were positively correlated with metagenomics-data-derived HDC values ($r = 0.81$ Pearson's correlation, $p = 9.3 \times 10^{-11}$; see ref [13]). We re-calculated the HDCs using our methods and found they were highly correlated with theirs ($r = 0.978$ Pearson's correlation, $p < 2.2e-16$; Table S5). These results further validated the reliability and accuracy of metagenomics-derived HDCs.

We identified 46 HDC-correlated species (Control + Baseline group, Spearman correlation, P-value < 0.001), most of which were also differential-species (31 of 47 CD-signature species) that showed significant abundance changes between healthy controls and untreated patients (Control + Baseline group, Wilcoxon rank sum test, adjusted p-value < 0.05, Fig. 3a, Table S6 and Table S7). *Akkermansia muciniphila* and *Bacteroides caccae* as mucus-degrading commensal species, were expectedly reduced with increasing HDCs, because impaired gut was insufficient to secrete mucus [33]. Another control-enriched bacterial marker, *Eubacterium ventriosum*, was previously identified to be negatively associated with fundamental components of eukaryotic cell membranes [34]. Similarly, differential pathways partly overlapped with HDC related pathways, including those involved in carbohydrate, protein and glycogen metabolism, the decreased abundances of which were known to associated with nutrient deficiency and dysfunction of intestine (Table S8 and Table S9) [31, 35, 36].

We also built random forest classifiers using species and pathways abundances for CD and did 10 times repeated 10-fold cross-validation. Similar to CRC, we found that adding HDC to the input data could improve prediction performance (AUC increased from 0.94 to 0.95 based on species profile; increased from 0.90 to 0.92 based on pathways profile; Figure S1); similar to CRC, we found that HDC was ranked as a top important feature (1st in this case), and majority of top ten features were HDC-correlated (Fig. 3b). Interestingly, although overlapped significantly, these species are quite different from those in CRC (Table S10) in terms of their changes and importance in patient stratification (Fig. 3b), likely due to differences of disease localizations and microenvironments: CD commonly occurred in the terminal part of ileum and present an inflammatory habitat for microbes, while CRC appearing as tumor microenvironment occurred in the colorectum [37, 38]. Nonetheless, it appears that elevated HDC is a common feature of intestinal diseases, while different diseases can be distinguished by their different gut dysbiosis profiles.

HDC and related dysbiosis signified clinical treatment outcomes

The CD patients we analyzed were treated with diet intervention or anti-TNF antibodies; the outcomes were evaluated with fecal metagenomics sequencing at week 1, 4 and 8 after the interventions [13]. We found that the HDCs were significantly decreased over time (Fig. 4a). As expected, HDC correlates significantly with fecal calprotectin (FCP; Pearson's correlation = 0.498, $p < 2.2e-16$, Figure S2), a clinical

indicator of intestinal inflammation released by neutrophils. However, concentrations of fecal calprotectin were only associated with three altered species in CD, indicating that HDC is a better biomarker related with dysbiosis than fecal calprotectin. Strikingly, we found 23 of the HDC-correlated species showed coordinated changes with HDC, i.e. species that were positively (negatively) correlated with HDC in the Control + Baseline group decreased (increased) with the decreasing HDCs (Kruskal-Wallis rank sum test, adjusted p -value < 0.05 , Figure S3), suggesting that the intervention that reduced fecal HDCs could globally reverse the gut dysbiosis in a species-specific manner. Such a conclusion was further supported by the observation that the correlations between HDC and some of the species were consistent in the Control + Baseline, Week1, Week4 and Week8 groups (Fig. 3a).

We then investigated the effects of classifiers based on HDC and gut microbiome in predicting response to CD therapy (see Methods). As we expected, including HDC to the models could improve performances (Fig. 4b, Figure S4); again, we found that models based on HDC related species performed better than models based on altered species. These results suggested we need reform the previous thinking that considers only changed species as biomarkers of patients, because there were some species whose alterations didn't reach the significance threshold (e.g. $fdr < 0.05$) but had a tendency. Besides, according to accuracies of classifiers built on pathways, we hypothesized that the microbial functional network didn't change a lot during treatment, even if the patients had a turn for the better (Figure S4). To confirm our hypothesis above, we collected another metagenomics dataset of CD patients for external validation. Interestingly, when constructed on HDC and species, HDC related classifier had highest value of AUC (AUC = 0.71, Fig. 4c), while the models built on pathway profiles appeared the trend but none of AUCs are over 0.65, probably due to the incompleteness of restoration in microbial metabolism (Table S11). Most of the key features of HDC related classifier are consistent with foregoing results that several HDC related species tended to recover when patients were under treatment (Figure S5). The excellent performance of the classifiers confirmed our inference that HDC related features had the potential to be signatures in classifying therapeutic response.

Discussion

In this study, we showed that host DNA contents (HDCs) in fecal metagenomic data were significantly elevated in patients of intestinal diseases, and thus could be used as a quantitative indicator for compromised intestinal barrier (CIB). CIB can increase the host-derived contents including epithelial cells and/or blood to be shed into intestinal lumen, alter the local gut environment and facilitate gut microbiota dysbiosis in view of the reciprocal relationship between gut microbiota and the host [39, 40]. As we expected, HDCs as a proxy of CIB, correlated significantly with many disease-altered species and metabolic pathways in CRC and CD, and can also be used as a quantitative indicator of gut microbiota dysbiosis. So far researchers have mostly focused on the potential of gut microbes as non-invasive biomarkers solely, or together with an extra test indicating CIB, such as FOBT and fecal calprotectin, which are fast but low-sensitive and low-specific. Our results suggested that CIB could be quantified as HDCs from metagenomics data, that were directly proportional with concentrations of fecal calprotectin.

As we have expected, including HDC as an additional feature, we obtained better machine learning models in patient stratification in both CRC and CD.

We also showed that HDC can be used as an indicator for effective treatment. HDCs were reduced significantly during diet or drug intervention in CD patients, which were accompanied by the recovery of many CD-related species. FCP correlated with only a few of the species, suggesting that HDC can be a better indicator for the global recovery of gut dysbiosis. Again, machine learning models including HDC achieved better performance in predicting treatment responses in patients.

Surprisingly, we found that the overall model performance based on HDC-correlated features was better than the differential features (i.e. taxonomic or functional features that showed significant differences between patients and healthy controls), although they overlapped significantly. These results suggest that the perturbation of important species could also contribute to disease development, even though the differences were not statistically significant.

In silico removal of host DNAs from metagenomics data is a recommended procedure [41], in part due to the considerations of contamination. Our results indicate that the metagenomics data can validate itself by looking at the correlated changes in HDC and related gut microbial species: a sudden increase in HDC without matching alterations in related bacteria is a strong indication of contamination. This line of reasoning can be applied to any host-produced molecules identified from feces, such as DNA, RNAs, proteins, metabolites and even cells, and would pave the way for extracting more host related information directly from fecal samples using multi-omics techniques and making use of them without worrying too much about contamination. As we have shown in this study, host related information directly extracted from fecal samples is reliable and useful.

In summary, we found that compromised intestinal barrier, as indicated by elevated human DNA contents (HDCs) in feces, is a common feature of intestinal diseases; HDC could be a promising biomarker for intestinal diseases because it signified the abundances changes of most of disease-related species, ranked as the top contributor to machine learning models for patient stratification and treatment response.

Conclusions

We identified that intestinal injury, manifestng as increased host shedding cells in faeces were associated with gut microbiome dysbiosis, and microbial community could be reversed during treatment along with reduced host DNA contents (HDCs). We constructed metagenomics-based classifiers with high performances in predicting patients with enteropathy and treatment response. Our results indicated the combination of HDCs and microbes could better reflect gut health as a potential biomarker obtaining from simply metagenomics.

Methods

Metagenomics data analysis

A total of 354 CRC patients, 112 CD patients and 382 controls from nine fecal metagenomics datasets were included in this study for classifier construction and external validation. Raw sequencing reads and metadata of the seven human colorectal cancer (CRC) metagenomics datasets were obtained from European Nucleotide Archive (ENA) under the following ENA project identifiers: PRJEB10878 [11], PRJEB27928 [15], PRJEB7774 [12], PRJEB12449 [14], and PRJEB6070 [10], PRJNA447983 [16] (cohort 1), and PRJDB4176 [15]. Raw sequencing reads and metadata of the Crohn's disease metagenomics dataset were obtained from NCBI SRA database under SRA ID: SRP057027 [13] for model construction and PRJNA384246 for external validation [19]. More details, including the nationality and age of these subjects, can be found in Table S1.

To remove adapters and low quality of bases, raw reads were filtered and trimmed by Trimmomatic [42] v3.6, using the Truseq3 adapter files and option with MINLEN cutoff 50. To estimate the human DNA contents (HDC) in metagenomics sequencing reads, the remaining reads (clean reads) were aligned to the human reference genome (hg19) using bowtie2 [43] (version 2.3.4.3); the HDC of a sample was calculated as the percentage of mapped reads out of total clean reads in the sample. The human DNA contents measured by quantitative PCR (QPCR) results in CD dataset were obtained from the corresponding publication by Lewis and colleagues [13]. Reads mapped to the human genome were removed before subsequent analyses. Taxonomic abundances of all metagenomic samples were quantified using MetaPhlan2 [44]. HUMAnN2 [45] was used to calculate relative pathway abundances via mapping reads to ChocoPhlan database and full UniRef90 database.

In each project except PRJNA384246 which was for external validation, to remove noise, species with max abundance < 0.1% in all samples as well as species whose average abundance across all samples below 0.01% were removed from further analyses. Similarly, pathways with zero value in at least 15% samples and with maximum relative abundances less than 1×10^{-6} in all samples of a project were also removed. The abundance data were then loaded into R and analyzed (<https://www.r-project.org>; version 3.5.1).

Statistical analyses

Wilcoxon Rank Sum Test was used to detect significant between-group differences in relative abundances of taxonomic- and pathway- features; features with adjusted P-value < 0.05 in at least two datasets of CRC were deemed significant; Similarly, differential features with adjusted P-value < 0.05 between controls and untreated patients (marked as baseline) in CD dataset were deemed significant. Spearman correlation was used to find HDC correlated species and pathways, features with P-value < 0.05 in at least two datasets of CRC were selected as significantly correlated features. For CD dataset, HDC related species and pathways with P-value < 0.001 were identified in controls and untreated patients using Spearman correlation. Besides, for determining the relationships between HDCs and species during the treatment, those identified HDC-related species were used to compute their spearman correlations

with HDCs in each treatment period (Week1, week 4 and week8). Also we used Kruskal-wallis test to examine which HDC-related species decreased significantly during therapy.

Classifiers construction

The randomForest package in R was used to build mathematic classification models (classifiers) that are capable of distinguishing patients and tumor-free participants, extract features that can be used to discriminate different phenotype groups and calculate feature importance scores. createMultiFolds algorithm was used to split dataset into 10 folds repeatedly to avoid biases due to simply one split.

For the CRC data, a so-called leave-one-dataset-out (LODO) analysis was also performed in order to evaluation cross-study performance of the obtained classifiers. In LODO analyses, all datasets except the one used for model testing were pooled as a training dataset which would be implemented the within-dataset ten-fold cross-validation; LODO was performed for each dataset in turn and were repeated 10 times, for all the seven CRC datasets. The LODO training dataset prediction accuracy was measured through ten times repeated ten-fold cross-validation.

For the CD data, 10 times repeated ten-fold cross-validation was used to assess the within-dataset accuracy of the resulting classifiers. We first utilized the data of controls and baseline for building classifiers to distinguish CD patients from controls. Then we constructed classifiers for predicting treatment response, only considering patients with complete longitudinal records whose FCP over 250 $\mu\text{g/g}$ at baseline [13]. We defined response to therapy as a decrease in FCP to $\leq 250 \mu\text{g/g}$ in a given period. For external validation, the information of therapeutic response was obtained from original article, which estimated clinical response according to HBI and SCCAI [19].

Abbreviations

CIB
Compromised intestinal barrier
HDC
Host DNA content
CRC
Colorectal cancer
CD
Crohn's disease
IBD
Inflammatory bowel disease
FCP
Fecal calprotectin
LODO
Leave-one-dataset-out
QPCR

Quantitative polymerase chain reaction

AUC

Area under the receiver-operating characteristics curve

Declarations

Ethics approval and consent to participate

From public database and original researches we downloaded raw sequencing data and metadata, which were approved by their corresponding ethics committee. Except total human DNA abundances served as a proxy of shedding cells from human and present in stools, we didn't use any other information of human genome, such as mutations and gene abundances.

Consent for publication

Not applicable.

Availability of data and materials

All R codes are available at

https://github.com/evolgeniusteam/HumanDNAContents_in_gut_metagenomics; also available are instructions for users to reproduced all our analyses, including figures, supplementary figures and statistics. The datasets generated during the current study are not publicly available due to file size but are available from the corresponding author W.H.C. on reasonable request.

Competing interests

The authors declare no competing interests.

Funding

This work was partly supported by National Key Research and Development Program of China 2018YFC0910502 (to W.H.C.), National Natural Science Foundation of China (61932008, 61772368, 61572363, all to X.M.Z.), National Key R&D Program of China (2018YFC0910500, to X.M.Z.), Natural Science Foundation of Shanghai (17ZR1445600, to X.M.Z.), Shanghai Municipal Science and Technology Major Project (2018SHZDZX01, to X.M.Z.) and ZJLab.

Authors' contributions

W.H.C. and X.M.Z. designed the study. P.J. collected and analyzed the CRC data, S.L. collected and analyzed the Crohn's Disease data. S.W. coordinated the data downloads and analysis. X.M.Z contributed to the mathematical modeling and interpretation. W.H.C. and P.J. wrote the manuscript with all authors contributing to the writing and providing feedbacks. All authors read and approved the final version of the manuscript.

Acknowledgements

Not applicable.

References

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A: **Colorectal cancer statistics, 2017.** *CA Cancer J Clin* 2017, **67**(3):177-193.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: **Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.** *CA Cancer J Clin* 2018, **68**(6):394-424.
3. Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellise M, Esteban L, Kaminski MF *et al.*: **Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years.** *Gut* 2019.
4. Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, De P, Tervonen H, Walsh PM, Bucher O *et al.*: **Changes in colorectal cancer incidence in seven high-income countries: a population-based study.** *Lancet Gastroenterol Hepatol* 2019.
5. M'Koma AE: **Inflammatory bowel disease: an expanding global health problem.** *Clin Med Insights Gastroenterol* 2013, **6**:33-47.
6. Frank C, Sundquist J, Yu H, Hemminki A, Hemminki K: **Concordant and discordant familial cancer: Familial risks, proportions and population impact.** *Int J Cancer* 2017, **140**(7):1510-1516.
7. Foulkes WD: **Inherited susceptibility to common cancers.** *N Engl J Med* 2008, **359**(20):2143-2153.
8. Knights D, Silverberg MS, Weersma RK, Gevers D, Dijkstra G, Huang H, Tyler AD, van Sommeren S, Imhann F, Stempak JM *et al.*: **Complex host genetics influence the microbiome in inflammatory bowel disease.** *Genome Med* 2014, **6**(12):107.
9. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA *et al.*: **Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.** *Genome Res* 2012, **22**(2):299-306.
10. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Bohm J, Brunetti F, Habermann N *et al.*: **Potential of fecal microbiota for early-stage detection of colorectal cancer.** *Mol Syst Biol* 2014, **10**:766.
11. Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y *et al.*: **Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer.** *Gut* 2017, **66**(1):70-78.
12. Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z *et al.*: **Gut microbiome development along the colorectal adenoma-carcinoma sequence.** *Nat Commun* 2015, **6**:6528.
13. Lewis James D, Chen Eric Z, Baldassano Robert N, Otley Anthony R, Griffiths Anne M, Lee D, Bittinger K, Bailey A, Friedman Elliot S, Hoffmann C *et al.*: **Inflammation, Antibiotics, and Diet as Environmental**

- Stressors of the Gut Microbiome in Pediatric Crohn's Disease.** *Cell Host & Microbe* 2015, **18**(4):489-500.
14. Vogtmann E, Hua X, Zeller G, Sunagawa S, Voigt AY, Hercog R, Goedert JJ, Shi J, Bork P, Sinha R: **Colorectal Cancer and the Human Gut Microbiome: Reproducibility with Whole-Genome Shotgun Sequencing.** *PLoS One* 2016, **11**(5):e0155362.
 15. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A, Ponnudurai R *et al.*: **Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer.** *Nat Med* 2019, **25**(4):679-689.
 16. Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, Beghini F, Manara S, Karcher N, Pozzi C *et al.*: **Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation.** *Nat Med* 2019, **25**(4):667-678.
 17. Vila AV, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang XF, Tigchelaar EF *et al.*: **Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome.** *Sci Transl Med* 2018, **10**(472).
 18. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee BH, Lomer MCE, Parkes GC, Selinger C *et al.*: **British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.** *Gut* 2019, **68**(Suppl 3):s1.
 19. Ananthakrishnan AN, Luo CW, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ: **Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.** *Cell Host & Microbe* 2017, **21**(5):603-+.
 20. Michielan A, D'Inca R: **Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut.** *Mediators Inflamm* 2015, **2015**:628157.
 21. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE *et al.*: **Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.** *Nature* 2012, **491**(7423):254-258.
 22. Jobin C: **CRC—all about microbial products and barrier function?** *Nature Reviews Gastroenterology & Hepatology* 2012, **9**:694.
 23. Camilleri M: **Leaky gut: mechanisms, measurement and clinical implications in humans.** *Gut* 2019.
 24. Klaassen CHW, Jeunink MAF, Prinsen CFM, Ruers TJM, Tan ACITL, Strobbe LJA, Thunnissen FBJM: **Quantification of Human DNA in Feces as a Diagnostic Test for the Presence of Colorectal Cancer.** *Clinical Chemistry* 2003, **49**(7):1185.
 25. Kim M, Ashida H, Ogawa M, Yoshikawa Y, Mimuro H, Sasakawa C: **Bacterial Interactions with the Host Epithelium.** *Cell Host & Microbe* 2010, **8**(1):20-35.
 26. Vincent C, Mehrotra S, Loo VG, Dewar K, Manges AR: **Excretion of Host DNA in Feces Is Associated with Risk of Clostridium difficile Infection.** *J Immunol Res* 2015, **2015**:246203-246203.
 27. Nairz M, Schroll A, Sonnweber T, Weiss G: **The struggle for iron - a metal at the host-pathogen interface.** *Cell Microbiol* 2010, **12**(12):1691-1702.

28. Wu SG, Rhee KJ, Albesiano E, Rabizadeh S, Wu XQ, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F *et al*: **A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses.** *Nature Medicine* 2009, **15**(9):1016-U1064.
29. Wang TT, Cai GX, Qiu YP, Fei N, Zhang MH, Pang XY, Jia W, Cai SJ, Zhao LP: **Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers.** *Isme J* 2012, **6**(2):320-329.
30. Koropatkin NM, Cameron EA, Martens EC: **How glycan metabolism shapes the human gut microbiota.** *Nature Reviews Microbiology* 2012, **10**(5):323-335.
31. Louis P, Hold GL, Flint HJ: **The gut microbiota, bacterial metabolites and colorectal cancer.** *Nature Reviews Microbiology* 2014, **12**(10):661-672.
32. Riestler M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G *et al*: **Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.** *J Natl Cancer Inst* 2014, **106**(5).
33. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A *et al*: **A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility.** *Cell* 2016, **167**(5):1339-+.
34. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser H, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ *et al*: **Gut microbiome structure and metabolic activity in inflammatory bowel disease.** *Nat Microbiol* 2019, **4**(2):293-305.
35. Bindels LB, Delzenne NM: **Muscle wasting: The gut microbiota as a new therapeutic target?** *The International Journal of Biochemistry & Cell Biology* 2013, **45**(10):2186-2190.
36. Kanungo S, Wells K, Tribett T, El-Gharbawy A: **Glycogen metabolism and glycogen storage disorders.** *Ann Transl Med* 2018, **6**(24):474-474.
37. Schirmer M, Garner A, Vlamakis H, Xavier RJ: **Microbial genes and pathways in inflammatory bowel disease.** *Nature Reviews Microbiology* 2019, **17**(8):497-511.
38. Keum N, Giovannucci E: **Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.** *Nat Rev Gastro Hepat* 2019, **16**(12):713-732.
39. Maynard CL, Elson CO, Hatton RD, Weaver CT: **Reciprocal interactions of the intestinal microbiota and immune system.** *Nature* 2012, **489**(7415):231-241.
40. Brown EM, Sadarangani M, Finlay BB: **The role of the immune system in governing host-microbe interactions in the intestine.** *Nat Immunol* 2013, **14**(7):660-667.
41. Knight R, Vrbanac A, Taylor BC, Aksenov A, Callewaert C, Debelius J, Gonzalez A, Kosciolek T, McCall LI, McDonald D *et al*: **Best practices for analysing microbiomes.** *Nat Rev Microbiol* 2018, **16**(7):410-422.
42. Bolger AM, Lohse M, Usadel B: **Trimmomatic: a flexible trimmer for Illumina sequence data.** *Bioinformatics* 2014, **30**(15):2114-2120.

43. Langmead B, Salzberg SL: **Fast gapped-read alignment with Bowtie 2.** *Nature methods* 2012, **9**(4):357-359.
44. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C: **Metagenomic microbial community profiling using unique clade-specific marker genes.** *Nature methods* 2012, **9**(8):811-814.
45. Franzosa EA, McIver LJ, Rahnavard G, Thompson LR, Schirmer M, Weingart G, Lipson KS, Knight R, Caporaso JG, Segata N *et al.*: **Species-level functional profiling of metagenomes and metatranscriptomes.** *Nature methods* 2018, **15**(11):962-968.

Supplementary Files Legend

Additional file 1: Table S1. A list of CRC and CD projects used in this study and the numbers of controls and cases.

Additional file 2: Table S2. Metadata of participants in CRC projects and their HDC%. HDC means the human DNA content.

Additional file 3: Table S3. Species that correlated with HDC in more than two CRC datasets statistically. Species whose Spearman p-value <0.05 in at least two projects were deemed as HDC correlated species. The column overlap = "1" means that the species is a signature feature whose abundance were significantly different in patients when compared with controls.

Additional file 4: Table S4. Pathways that correlated with HDC in more than two CRC datasets statistically. Pathways whose Spearman p-value <0.05 in at least two projects were deemed as HDC correlated Pathways. The column overlap = "1" means that the pathway is a signature feature whose abundance were significantly different in patients when compared with controls.

Additional file 5: Table S5. A list of samples of the CD project and their HDC% produced by two ways. Our HDC% were generated using Bowtie2, while Lewis's HDC% were generated using BMtagger (pmid :26468751).

Additional file 6: Table S6. Species that correlated with HDCs in untreated patients and controls from CD project (P-value < 0.001). We calculated Spearman correlation between HDC and HDC-related species in each stage of patients and controls.

Additional file 7: Table S7. Differential species in the Control+Baseline group of CD (Adjusted P-value <0.05). The column overlap = "1" means that the species were correlated with HDC (Spearman correlation P-value < 0.001, see Table S6).

Additional file 8: Table S8. Pathways that correlated with HDCs in untreated patients and controls from CD project (P-value < 0.001). We calculated Spearman correlation between HDC and HDC-related pathways in each stage of patients and controls.

Additional file 9: Table S9. Differential pathways in the Control+Baseline group of CD (Adjusted P-value <0.05). The column overlap = "1" means that the pathways were correlated with HDC (Spearman correlation P-value < 0.001, see Table S8).

Additional file 10: Table S10. Overlapped features of the top 30 important features between CD and CRC. The columns "Importance_in_CRC" and "Importance_in_CD" mean the median importance scores of the top 30 features in the CRC models and CD models, respectively. The columns "ranking_in_CRC" and "ranking_in_CD" mean the importance degrees of the shared features in the CRC models and CD models separately.

Additional file 11: Table S11. AUC of classifiers based on species/pathways profiles (SRP057027) when predicting treatment response of external dataset (PRJNA384246). Features column means which type of features used for constructing random forest model.

Additional file 12: Figure S1. AUC of random forest classifiers based on species/pathways profiles (SRP057027) for predicting untreated CD patients from controls.

Additional file 13: Figure S2. Pearson correlation between HDC and fecal calprotectin in CD dataset.

Additional file 14: Figure S3. Distributions of consistently HDC-correlated species in controls and patients with complete longitudinal treatment of CD dataset. Y-axis is log₁₀ transformed relative abundances.

Additional file 15: Figure S4. AUC of random forest classifiers based on pathways profiles (SRP057027) for predicting treatment response.

Additional file 16: Figure S5. Ranking of feature importance in the HDC + HDC-related species model for predicting treatment response. The models were trained by using HDC values and relative abundances of HDC-related species as input; only the data of the patients with complete longitudinal treatment were used. The importance scores were reported by the Random forest models. The features were ranked according to the median importance scores from 100 repeated results of cross-validation analysis (see Methods). Light blue: HDC; Red: Dif-species that correlated with HDC; Grey: other species. Those marked a star in front of the name were the consistent HDC-related species shown in Figure S3.

Figures




Figure 1

Human DNA contents (HDCs) were significantly elevated in feces of CRC patients, and correlated with microbial- and functional- biomarkers. a, HDCs, calculated as the percentage of gut metagenomics sequencing reads mapped to the human genome, were significantly higher in CRC (dark red box) than healthy controls (grey box) in seven recently published datasets (Wilcoxon Rank Sum Test, see Methods). b, Species that were significantly correlated with HDCs in two and more CRC datasets (Spearman Rank

Correlation, p-value < 0.05, see Methods). Correlations were calculated using both CRC patients and healthy controls. Red: species with differential abundances between CRC and controls in two and more CRC datasets (Wilcoxon rank sum test, adjusted p-value < 0.05, see Methods). c, Metabolic pathways that were significantly correlated with HDCs in three and more CRC datasets. Correlations were calculated using both CRC patients and healthy controls. Red: pathways with differential abundances between CRC and controls in two and more CRC datasets (Wilcoxon rank sum test, adjusted p-value < 0.05, see Methods).




Figure 2

HDC and correlated species and metabolic functions contribute significantly to patient stratification in LODO analysis in CRC. a, Predictive performances as AUC values obtained using leave-one-dataset-out (LODO) analysis by training the models on the species abundances. The AUC values were averaged from repeated results of 10-fold validation analysis. Dif-species: species whose abundances are significantly different between CRC and controls in at least two datasets (Wilcoxon Rank Sum Test, see Methods); HDC-species: HDC-correlated species in at least two datasets; see Methods for details. All-species: models build on overall species. b, Ranking of feature importance in the HDC + All-species model. The models were trained by using HDC values and relative abundances of all species as input. The importance scores were reported by the LODO models. The features were ranked according to the median importance scores from 100 repeated results of 10-fold validation analysis. Light blue: HDC; Dark blue: HDC-species; Green: Dif-species; Red: Dif-species that correlated with HDC; Grey: other species. c, AUC values obtained using LODO analysis by training the models on the metabolic pathway abundances. Dif-pathways: pathways whose abundances are significantly different between CRC and controls (Wilcoxon Rank Sum Test, see Methods); HDC-pathways: HDC-correlated pathways; see Methods for details. All-pathways: models build on all pathways. d, Ranking of feature importance in the HDC + All-pathway model. The models were trained by using HDC values and relative abundances of all pathways as input. The importance scores were reported by the LODO models. Light blue: HDC; Dark blue: HDC-pathways; Green: Dif-pathways; Red: Dif-pathways that correlated with HDC; Grey: other pathways.

significance levels. b, Ranking of feature importance in the HDC + All-species model. The models were trained by using HDC values and relative abundances of all species as input; only the data of the healthy controls and untreated patients were used. The importance scores were reported by the Random forest models. The features were ranked according to the median importance scores from 100 repeated results of cross-validation analysis (see Methods). Light blue: HDC; Green: Dif-species; Red: Dif-species that correlated with HDC; Grey: other species.




Figure 4

HDCs were reduced during treatment, and could improve the performance of machine learning models in predicting treatment response of CD patients. a, HDCs were significantly reduced along treatment intervention. b, Predictive results as AUC values obtained from ten-time repeated 10-fold cross-validation models for classifying treatment response. HDC-species: HDC-correlated species in untreated patients and controls (see Methods for details); Dif-species: species whose abundances are significantly different between untreated patients (Wilcoxon Rank Sum Test, see Methods); All-species: models build on overall species. c, External validation of models based on HDC and species showing in Figure 4b. Accuracies were displayed as ROC plot, in which x axis is false positive rate, y axis is true positive rate, and AUC is the area under the curve.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS5.pdf](#)
- [TableS9.xlsx](#)
- [TableS10.xlsx](#)
- [TableS11.xlsx](#)
- [FigureS3.pdf](#)
- [TableS2.xlsx](#)
- [TableS3.xlsx](#)
- [TableS1.xlsx](#)
- [TableS5.xlsx](#)
- [TableS4.xlsx](#)
- [TableS6.xlsx](#)
- [TableS7.xlsx](#)
- [FigureS4.pdf](#)
- [FigureS1.pdf](#)
- [FigureS2.pdf](#)
- [TableS8.xlsx](#)